Amit V Patil
Government Medical College, Thiruvananthapuram
8 Papers
61 Citations
Amit V Patil is an academic researcher from Government Medical College, Thiruvananthapuram. The author has contributed to research in topics: Breast cancer & Estrogen receptor. The author has an hindex of 6, co-authored 8 publications.
Chat about Author
Papers
E-Cadherin as a diagnostic biomarker in breast cancer
Rajeev Singhai,Vinayak W. Patil,Sanjog R Jaiswal,Shital D Patil,Mukund B Tayade,Amit V Patil +5 more
TL;DR: E-cadherin immunohistochemistry is helpful in classifying breast cancer cases with indeterminate histopathologic features and shows no correlation to currently established prognostic variables.
185
Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
Vinayak W. Patil,Rajeev Singhai,Amit V Patil,Prakash Dattatray Gurav +3 more
- 16 Mar 2011
TL;DR: In this article, the authors investigated the clinicopathological characteristics and prognostic indicators of lymph node-negative triple-negative breast cancer, which is defined as being negative for the estrogen receptor (ER), the progesterone receptor (PgR), and the human epidermal growth factor receptor 2 (HER-2/neu).
Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women
TL;DR: It is concluded that patients with group 2 breast cancer were younger post-menopausal women, with tumors moderately differentiated, HER-2/neu score 0 or 1+ and with lower Ki-67 proliferation rate.
17
•Journal Article
Immunohistochemical (IHC) HER-2/neu and Fluorescent- In-Situ Hybridization (FISH) Gene Amplification of Breast Cancer in Indian Women
TL;DR: IHC can be used firstly to screen the HER-2/neu status, and FISH can be use as a supplementary role to IHC and 2+ and some negative cases, and only those cases with Herceptin (Trastuzumab) positive should be treated with Herception.
10
Ki-67 biomarker in breast cancer of Indian women.
TL;DR: The clinical utility of early changes in biological marker expression during chemotherapy remains unclear and clinical decision-making should not be based upon individual biological tumor biomarker profiles.
9